Loading...
XJPX
4974
Market cap848mUSD
Jun 11, Last price  
1,144.00JPY
Name

Takara Bio Inc

Chart & Performance

D1W1MN
XJPX:4974 chart
P/E
P/S
3.42
EPS
Div Yield, %
1.49%
Shrs. gr., 5y
Rev. gr., 5y
-2.64%
Revenues
40.32b
-10.48%
20,982,000,00020,278,000,00018,913,000,00019,325,000,00018,737,000,00019,578,000,00020,564,000,00023,905,000,00025,969,000,00029,729,000,00029,375,000,00032,312,000,00035,841,000,00034,565,000,00046,086,000,00067,699,000,00078,142,000,00043,505,000,00045,039,000,00040,318,000,000
Net income
-9.60b
L
320,000,000679,000,000642,000,000591,000,000605,000,0001,023,000,0001,462,000,0001,470,000,000963,000,0001,334,000,0001,352,000,0002,335,000,0003,657,000,0003,819,000,0009,547,000,00019,849,000,00016,012,000,0001,480,000,0001,042,000,000-9,598,000,000
CFO
3.58b
-38.71%
3,128,000,0002,018,000,0002,265,000,0003,174,000,0002,093,000,0002,366,000,0002,226,000,0002,251,000,0003,558,000,0003,021,000,0003,584,000,0003,935,000,0005,783,000,0006,339,000,00013,943,000,0006,985,000,00036,897,000,0001,711,000,0005,844,000,0003,582,000,000
Dividend
Mar 28, 202517 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Takara Bio Inc., a subsidiary of Takara Holdings Inc., is a Japan-based biotechnology firm established in Kusatsu in 2002. The company operates globally, with a presence in Japan, China, other Asian countries, the United States, and Europe, focusing on three primary areas: general biotechnology, contract development and manufacturing (CDMO) services, and gene therapy. The company offers a diverse portfolio of scientific products, including a wide array of reagents and specialized instruments. These encompass tools for genetic research and testing, in vitro diagnostic solutions for viral detection (such as those for coronaviruses), analytical reagents, and advanced single-cell analysis systems. They also supply essential reagents for gene expression studies, fluorescent protein series, genome-editing research, iPS cell research, and products for culturing and differentiating stem cells. These offerings are marketed under prominent brands like TaKaRa, Clontech, and Cellartis. In addition to its product line, Takara Bio provides extensive contract services. For regenerative medicine, this includes the production of viral vectors and gene-modified cells, alongside rigorous quality and safety testing, and comprehensive cell banking services. Their gene analysis and testing services cover a broad spectrum, from DNA sequencing and gut microbiome analysis to in-depth profiling of cancer-associated genes and the creation of cell lines through genome editing. Furthermore, Takara Bio is actively engaged in developing foundational platform technologies to support the advancement of biologics, particularly within the field of gene therapy.
IPO date
Dec 07, 2004
Employees
1,793
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT